A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

The day after Pfizer Inc’s patent for Viagra expired in Brazil, Carlos Sanchez flooded pharmacies with his generic erectile dysfunction pills. It was a day his army of lawyers, researchers and ...

NEW YORK (Reuters) - Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core ...

but Pfizer’s recent acquisition of spree does add specific risks around capital allocation. However, what’s not usual here is the valuation, which looks absurdly low after a 50%+ drop in the ...

Pfizer (PFE, Financials) announced plans to invest $1 billion in China over the next five years to enhance research and development of innovative drugs. Jean-Christophe Pointeau, president of ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

NEW YORK, Nov 12 (Reuters) - Pfizer (PFE.N), opens new tab is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value ...